Permin H, Koch C, Høiby N, Christensen H O, Møller A F, Møller S
J Antimicrob Chemother. 1983 Jul;12 Suppl A:313-23. doi: 10.1093/jac/12.suppl_a.313.
Two open randomized cross-over studies were undertaken comparing ceftazidime to tobramycin and ceftazidime to tobramycin plus carbenicillin in 13 and 15 cystic fibrosis (CF) patients, respectively, with chronic bronchopulmonary Pseudomonas aeruginosa infection. The difference in lung function improvement was statistically better in terms of FEV1 and FVC for the ceftazidime group in the study versus tobramycin plus carbenicillin. Patients receiving ceftazidime showed a tendency for a greater long-term benefit in lung function as measured at 1 and 2 months after treatment than patients receiving the other antibiotics. Development of resistance against both ceftazidime and carbenicillin was seen regularly and was not prevented by combination therapy with tobramycin. No resistance developed when tobramycin was used as monotherapy. Serum concentration curves for ceftazidime fitted a two compartment first order open model in CF patients and showed a distribution volume of 40% of the body weight and a final serum half-life of 1.8 h. One case of Type III hypersensitivity reaction was seen during ceftazidime treatment. Ceftazidime seems to be an effective and safe antibiotic in the treatment of Ps. aeruginosa bronchopulmonary infection in CF patients, although these bacteria could not be eradicated.
开展了两项开放性随机交叉研究，分别在13例和15例患有慢性支气管肺铜绿假单胞菌感染的囊性纤维化（CF）患者中，比较头孢他啶与妥布霉素，以及头孢他啶与妥布霉素加羧苄西林的疗效。在该研究中，头孢他啶组在第一秒用力呼气容积（FEV1）和用力肺活量（FVC）方面，肺功能改善的差异在统计学上优于妥布霉素加羧苄西林组。与接受其他抗生素治疗的患者相比，接受头孢他啶治疗的患者在治疗后1个月和2个月时，肺功能显示出更大的长期获益趋势。对头孢他啶和羧苄西林的耐药性经常出现，且联合妥布霉素治疗无法预防。当妥布霉素作为单一疗法使用时，未出现耐药性。头孢他啶在CF患者中的血清浓度曲线符合二室一级开放模型，分布容积为体重的40%，血清终末半衰期为1.8小时。在头孢他啶治疗期间，出现了1例III型超敏反应。头孢他啶似乎是治疗CF患者铜绿假单胞菌支气管肺感染的一种有效且安全的抗生素，尽管这些细菌无法被根除。
